Butaclamol hydrochloride (AY-23,028): an early evaluation in severely ill schizophrenics.
D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005116:Extrapyramidal Tracts; D005133:Eye Movements; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy; D009127:Muscle Rigidity / Q000139:chemically induced; D010276:Parasympatholytics / Q000627:therapeutic use; D010919:Placebos; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014202:Tremor / Q000139:chemically induced
D010276:Parasympatholytics; D010919:Placebos; D011804:Quinolines; D014149:Tranquilizing Agents